Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016

Details for Mechanism ID: 18091
Country/Region: Democratic Republic of the Congo
Year: 2016
Main Partner: Pathfinder International
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $600,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $44,000
Care: TB/HIV (HVTB) $25,000
Care: Pediatric Care and Support (PDCS) $20,000
Laboratory Infrastructure (HLAB) $12,000
Strategic Information (HVSI) $6,000
Health Systems Strengthening (OHSS) $53,500
Biomedical Prevention: Injection Safety (HMIN) $15,000
Testing: HIV Testing and Counseling (HVCT) $94,500
Sexual Prevention: Other Sexual Prevention (HVOP) $40,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $30,000
Treatment: Adult Treatment (HTXS) $230,000
Treatment: Pediatric Treatment (PDTX) $30,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 2,667
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 1,780
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 22,852
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 7,137
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 34,436
HTS_TST Service Delivery Point (Facility): Index testing 2017 175
HTS_TST Service Delivery Point (Facility): Inpatient 2017 4,099
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 1,539
HTS_TST Service Delivery Point (Facility): Other PITC 2017 1,539
HTS_TST Service Delivery Point (Facility): Outpatient 2017 7,505
HTS_TST Service Delivery Point (Facility): Pediatric 2017 3,988
HTS_TST Service Delivery Point (Facility): PMTCT 2017 13,830
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 1,586
HTS_TST Service Delivery Point (Facility): VCT 2017 175
HTS_TST Sum of Aggregated Age/Sex <15 2017 4,447
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 29,989
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 34,436
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 90
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 62
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 416
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 248
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 15
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 15
LAB_PT CD4: Number of laboratories that perform this testing 2017 15
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 20
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 20
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 44
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 20
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 20
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 44
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 15
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 15
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 15
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 1
PMTCT_ART Already on ART at beginning of current pregnancy 2017 60
PMTCT_ART New on ART 2017 180
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 14,140
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 101
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 123
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 11
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 8
PMTCT_EID Sum of Infant Age disaggregates 2017 224
PMTCT_STAT By: Known positives at entry 2017 132
PMTCT_STAT By: Number of new positives identified 2017 120
PMTCT_STAT Number of new ANC and L&D clients 2017 14,575
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 14,140
PMTCT_STAT Sum of Positives Status disaggregates 2017 252
PP_PREV Aggregated Age/sex: <15 Female 2017 60
PP_PREV Aggregated Age/sex: <15 Male 2017 76
PP_PREV Aggregated Age/sex: 15+ Female 2017 584
PP_PREV Aggregated Age/sex: 15+ Male 2017 780
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 1,132
PP_PREV Total number of people in the target population 2017 1,411
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 11
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 120
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 16
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 151
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 324
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 292
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 371
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 19
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 304
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 44
TB_SCREENDX Screen Result: Screened Positive for TB 2017 412
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 792
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 1,033
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 89
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 104
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 2,052
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 68
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 597
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 85
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 770
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 1,509
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 1,587
TX_CURR Aggregated Age/Sex: <15 Female 2017 412
TX_CURR Aggregated Age/Sex: <15 Male 2017 277
TX_CURR Aggregated Age/Sex: 15+ Female 2017 2,669
TX_CURR Aggregated Age/Sex: 15+ Male 2017 757
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 4,102
TX_CURR Sum of Aggregated Age/Sex <15 2017 689
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 3,426
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 4,115
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 81
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 47
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 595
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 200
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 921
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 923
Cross Cutting Budget Categories and Known Amounts Total: $40,000
Gender: Gender Based Violence (GBV) $10,000
GBV Prevention
Gender: Gender Equality $30,000
Equity in HIV prevention, care, treatment and support
Capacity building
Monitoring and Evaluation